The Company’s strategy is to secure products that have been developed by other pharmaceutical and biomedical companies and that have successfully completed independent clinical trials and have been approved for market release by regulators such as the US Food and Drug Administration (FDA) and/or Conformite Europeene (CE). Helicon then manages the regulatory approvals programme in China and other North Asian markets through contracted expert regulatory advisers. Important selection criteria include the potential for a premium market, secure intellectual property and know how, technology and manufacturing processes that are difficult to reverse engineer, and a target rate of return on investment.
Selection Criteria
HOME
PRODUCTS